Interní Med. 2016; 18(5): 256-259 [Onkologie. 2015:9(6):298-303]

Diagnosis and treatment of chronic myelomonocytic leukemia - a view from clinical practice

doc. MUDr. Peter Rohoň, Ph.D.¹, MUDr. Petra Bělohlávková², MUDr. Zuzana Rusiňáková¹, doc. MUDr. Vít Procházka, Ph.D.¹, MUDr. Eva Kadlčková³, MUDr. Luděk Raida, Ph.D.¹, MUDr. Alžběta Zavřelová², prof. RNDr. Marie Jarošová, CSc.¹, doc. MUDr. Pavel Žák, Ph.D.², prof. MUDr. Karel Indrák, DrSc.¹

¹ Hemato-onkologická klinika FN a LF UP v Olomouci

² IV. interní hematologická klinika FN Hradec Králové

³ Hematologicko-transfuzní oddělení, Krajská nemocnice T. Bati Zlín, a.s.

Chronic myelomonocytic leukemia (CMML) is a hematopoietic stem cells disorder, it carries myelodysplastic and myeloproliferative features. CMML occurs rarely, especially in the elderly, and often transforms into acute myelogenous leukemia. Recently, in a large proportion of patients sophisticated molecular-biology technologies can determine mutations in epigenetic regulatory genes (e. g. TET2, ASXL1, …) that modify chromatin condensation and also gene expression. These facts support the inclusion of hypomethylating agents (HMA) in the standard treatment of CMML and opened the gates for the use of other new molecules. The aim of this paper is to describe concrete examples of current diagnostics and treatment of CMML and demonstrate the complexity of the new approaches.

Keywords: chronic myelomonocytic leukemia, hypomethylating agents, allogeneic stem cell transplantation

Published: December 1, 2016  Show citation